MNKD vs SYK: fair value comparison
MannKind Corporation and Stryker Corporation · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MNKD currently sits closer to the top of our discount ranking.
| MNKD | SYK | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $3.80 | $303.13 |
| 12-month range | $2.54–$6.01 | $294.73–$387.02 |
| Sector rank | #17 of 113 Healthcare | #21 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | — |
| DCF cross-check | Overvalued | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: MNKD fair value analysis · SYK fair value analysis